Integrated BioTherapeutics, Inc.-Product Pipeline Review-2015

Integrated BioTherapeutics, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07266CDB
  • |
  • Pages: 40
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Integrated BioTherapeutics, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Integrated BioTherapeutics, Inc.-Product Pipeline Review-2015', provides an overview of the Integrated BioTherapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Integrated BioTherapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Integrated BioTherapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Integrated BioTherapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Integrated BioTherapeutics, Inc.'s pipeline products

Reasons To Buy

Evaluate Integrated BioTherapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Integrated BioTherapeutics, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Integrated BioTherapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Integrated BioTherapeutics, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Integrated BioTherapeutics, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Integrated BioTherapeutics, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Integrated BioTherapeutics, Inc. Snapshot 5

Integrated BioTherapeutics, Inc. Overview 5

Key Information 5

Key Facts 5

Integrated BioTherapeutics, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

Integrated BioTherapeutics, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Integrated BioTherapeutics, Inc.-Pipeline Products Glance 11

Integrated BioTherapeutics, Inc.-Clinical Stage Pipeline Products 11

Phase I Products/Combination Treatment Modalities 11

Integrated BioTherapeutics, Inc.-Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

Integrated BioTherapeutics, Inc.-Drug Profiles 14

STEBVax 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

AT-62aa 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Monoclonal Antibody 3 for Staphylococcus Aureus Infections 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

panfilovirus (multivalent) vaccine 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

SEB-HuMab 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

staphylococcal aureus [serogroup A] (multivalent) vaccine 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

staphylococcus aureus (bivalent) vaccine 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

staphylococcus aureus (multivalent) vaccine 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Drugs for Staphylococcus Aureus Infections 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Monoclonal Antibodies for Ebola and Marburg Infections 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Monoclonal Antibody 1 for Staphylococcus Aureus Infections 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Monoclonal Antibody 2 for Staphylococcus Aureus Infections 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Monoclonal Antibody 4 for Staphylococcus Aureus Infections 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Integrated BioTherapeutics, Inc.-Pipeline Analysis 32

Integrated BioTherapeutics, Inc.-Pipeline Products by Target 32

Integrated BioTherapeutics, Inc.-Pipeline Products by Route of Administration 33

Integrated BioTherapeutics, Inc.-Pipeline Products by Molecule Type 34

Integrated BioTherapeutics, Inc.-Pipeline Products by Mechanism of Action 35

Integrated BioTherapeutics, Inc.-Recent Pipeline Updates 36

Integrated BioTherapeutics, Inc.-Dormant Projects 37

Integrated BioTherapeutics, Inc.-Locations And Subsidiaries 38

Head Office 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

Integrated BioTherapeutics, Inc., Key Information 5

Integrated BioTherapeutics, Inc., Key Facts 5

Integrated BioTherapeutics, Inc.-Pipeline by Indication, 2015 7

Integrated BioTherapeutics, Inc.-Pipeline by Stage of Development, 2015 9

Integrated BioTherapeutics, Inc.-Monotherapy Products in Pipeline, 2015 10

Integrated BioTherapeutics, Inc.-Phase I, 2015 11

Integrated BioTherapeutics, Inc.-Preclinical, 2015 12

Integrated BioTherapeutics, Inc.-Discovery, 2015 13

Integrated BioTherapeutics, Inc.-Pipeline by Target, 2015 32

Integrated BioTherapeutics, Inc.-Pipeline by Route of Administration, 2015 33

Integrated BioTherapeutics, Inc.-Pipeline by Molecule Type, 2015 34

Integrated BioTherapeutics, Inc.-Pipeline Products by Mechanism of Action, 2015 35

Integrated BioTherapeutics, Inc.-Recent Pipeline Updates, 2015 36

Integrated BioTherapeutics, Inc.-Dormant Developmental Projects,2015 37

List of Figures

Integrated BioTherapeutics, Inc.-Pipeline by Top 10 Indication, 2015 7

Integrated BioTherapeutics, Inc.-Pipeline by Stage of Development, 2015 9

Integrated BioTherapeutics, Inc.-Monotherapy Products in Pipeline, 2015 10

Integrated BioTherapeutics, Inc.-Pipeline by Top 10 Target, 2015 32

Integrated BioTherapeutics, Inc.-Pipeline by Top 10 Molecule Type, 2015 34

Integrated BioTherapeutics, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Integrated BioTherapeutics, Inc.; Integrated BioTherapeutics, Inc. - Key Therapeutics; Integrated BioTherapeutics, Inc. - Pipeline Overview and Promising Molecules; Integrated BioTherapeutics, Inc. - News; Integrated BioTherapeutics, Inc. - Latest Updates; Integrated BioTherapeutics, Inc. - Pipeline; Integrated BioTherapeutics, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101175
Site License
USD 3000 INR 202350
Corporate User License
USD 4500 INR 303525



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]